Aquestive amends bylaws to update stockholder meeting procedures and director nomination requirements

Aquestive Therapeutics, Inc.

Bylaws amended to eliminate requirement to re-notice adjourned meetings if time/date/place announced or in original notice.
Removed requirement to make stockholder list available for inspection during meetings.
Added enhanced director nomination requirements: background info, Universal Proxy Rule compliance, limit nominees to board seats.
Nominees must provide representation on voting/compensation arrangements and compliance with laws and company policies.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Aquestive Therapeutics, Inc.: Amended and restated Bylaws to update provisions on adjourned stockholder meetings, stockholder list inspection, and director nomination requirements, including compliance with Universal Proxy Rules (effective 2023-02-02).

Change: bylaw amendment
Effective: 2023-02-02

Exact text from the filing

On February 2, 2023, the Board of Directors (the “Board”) of Aquestive Therapeutics, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws, as amended (the “Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-002496

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.